Stockscreener 앱 받기
6.03
0.58%
-0.03
시간 외 거래:
6.03
Cvrx Inc 주식(CVRX)의 최신 뉴스
CVRx, Inc. (NASDAQ:CVRX) Shares Sold by Alliancebernstein L.P. - Defense World
CVRx, Inc. (NASDAQ:CVRX) Shares Acquired by JPMorgan Chase & Co. - Defense World
CVRx, Inc. (NASDAQ:CVRX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
(CVRX) Investment Analysis - news.stocktradersdaily.com
Cantor maintains CVRx stock with $20 target despite revenue miss By Investing.com - Investing.com India
Cantor maintains CVRx stock with $20 target despite revenue miss - Investing.com
William Blair Comments on CVRx’s Q1 Earnings (NASDAQ:CVRX) - Defense World
CVRx's SWOT analysis: barostim maker's stock faces growth hurdles By Investing.com - Investing.com India
CVRx stock slides on preliminary revenue miss - MSN
CVRx, Inc.: Overreaction Creates Buying Opportunity - Seeking Alpha
CVRx Insiders Lose Out As Stock Sinks To US$6.20 - simplywall.st
CVRx’s SWOT analysis: barostim maker’s stock faces growth hurdles By Investing.com - Investing.com India
CVRx's SWOT analysis: barostim maker's stock faces growth hurdles - Investing.com
Cantor Fitzgerald maintains CVRx stock Overweight rating By Investing.com - Investing.com South Africa
CVRx stock touches 52-week low at $6.36 amid market challenges By Investing.com - Investing.com South Africa
Top Midday Decliners - MarketScreener
CVRx stock drops on Q1 preliminary sales number miss - MassDevice
CVRx stock touches 52-week low at $6.36 amid market challenges - Investing.com
Cantor Fitzgerald maintains CVRx stock Overweight rating - Investing.com
Dow Jumps Over 1,100 Points; US Small Business Sentiment Falls In March - Benzinga
CVRx price target lowered to $14 from $19 at Lake Street - TipRanks
Assessing CVRx: Insights From 4 Financial Analysts - Benzinga
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Canaccord cuts CVRx stock target to $18, maintains Buy rating By Investing.com - Investing.com India
Top Premarket Decliners - MarketScreener
Canaccord cuts CVRx stock target to $18, maintains Buy rating - Investing.com
CVRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Investors to Contact the Firm Today! - ACCESS Newswire
CVRx (CVRX) Stock Drops as Preliminary Q1 2025 Revenue Disappoin - GuruFocus
CVRx stock slides on preliminary revenue miss (CVRX:NASDAQ) - Seeking Alpha
CVRx Sees Q1 Higher Revenue YOY, Missing Consensus -- Shares Fall After Hours - MarketScreener
CVRx Reports Preliminary First Quarter 2025 Financial Results - The Manila Times
CVRx Posts Mixed Q1 Earnings: 15% Growth Meets Headwinds as Expansion Continues - Stock Titan
(CVRX) Long Term Investment Analysis - news.stocktradersdaily.com
Bank of New York Mellon Corp Increases Stake in CVRx, Inc. (NASDAQ:CVRX) - Defense World
CVRx stock plunges 42% in wake of Q1 report, updated forecast - MSN
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Several Insiders Invested In CVRx Flagging Positive News - Yahoo
Cantor Fitzgerald maintains CVRx stock with $20 target By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains CVRx stock with $20 target - Investing.com
(CVRX) Trading Report - Stock Traders Daily
With A 29% Price Drop For CVRx, Inc. (NASDAQ:CVRX) You'll Still Get What You Pay For - Simply Wall St
Power Shift 25: Medtech firm's new CEO looks to 'build a world-class team'Minneapolis / St. Paul Business Journal - Minneapolis / St. Paul Business Journal
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Analyzing Co-Diagnostics (NASDAQ:CODX) and CVRx (NASDAQ:CVRX) - Defense World
CVRx, Inc. (NASDAQ:CVRX) Short Interest Down 9.8% in January - Defense World
CVRx, Inc. SEC 10-K Report - TradingView
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles - MSN
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles By Investing.com - Investing.com UK
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim - GlobeNewswire
Cvrx, Inc. Announces New Real-World Evidence Demonstrating Significant Reductions in Healthcare Utility with Barostim - Marketscreener.com
1.43%
자본화:
|
볼륨(24시간):